Mesoblast Limited (MEOBF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mesoblast Limited (MEOBF) with AI Score 67/100 (Buy). Mesoblast Limited is an Australian regenerative medicine company focused on developing cell-based therapies for inflammatory diseases and conditions. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Mesoblast Limited (MEOBF) Healthcare & Pipeline Overview
Mesoblast Limited, an Australian biotechnology firm, develops regenerative medicine products using its mesenchymal lineage cell technology. With a focus on inflammatory diseases and cardiovascular conditions, the company is currently undergoing Phase III clinical trials for its lead product, Remestemcel-L, and has established strategic partnerships to expand its reach and product offerings in the regenerative medicine space.
Investment Thesis
Mesoblast Limited presents a high-risk, high-reward investment opportunity within the regenerative medicine sector. The company's lead product, Remestemcel-L, is undergoing Phase III clinical trials for several indications, including SR-aGVHD and chronic heart failure. Successful trial outcomes and subsequent regulatory approvals could drive significant revenue growth. The company's strategic partnerships with Tasly, JCR Pharmaceuticals, and Grünenthal provide additional revenue streams and validation of its technology. However, the company's negative profit margin of -144.3% and negative gross margin of -35.5% highlight the financial risks associated with investing in a clinical-stage biotechnology company. Investors should closely monitor clinical trial results, regulatory decisions, and the company's cash burn rate.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $1.74 billion reflects investor expectations for Mesoblast's pipeline of regenerative medicine products.
- Phase III clinical trials underway for Remestemcel-L in multiple indications, including steroid-refractory acute graft versus host disease (SR-aGVHD) and chronic heart failure, represent potential near-term catalysts.
- Strategic partnerships with Tasly Pharmaceutical Group, JCR Pharmaceuticals Co. Ltd., and Grünenthal provide access to new markets and development expertise.
- Negative profit margin of -144.3% indicates the company is currently investing heavily in research and development.
- Debt-to-equity ratio of 23.52 suggests a moderate level of financial leverage.
Competitors & Peers
Strengths
- Proprietary mesenchymal lineage cell technology platform.
- Advanced clinical pipeline with Phase III assets.
- Strategic partnerships with established pharmaceutical companies.
- Experienced management team with expertise in regenerative medicine.
Weaknesses
- Negative profit margin and gross margin.
- Reliance on clinical trial success and regulatory approvals.
- High cash burn rate.
- Limited commercial infrastructure.
Catalysts
- Upcoming: Results from Phase III clinical trials for Remestemcel-L in SR-aGVHD are expected in late 2026.
- Upcoming: Regulatory decisions on Remestemcel-L for SR-aGVHD are anticipated in 2027.
- Ongoing: Enrollment and progress in Phase III clinical trials for chronic heart failure.
- Ongoing: Expansion of strategic partnerships and licensing agreements.
- Ongoing: Advancement of MPC-300-IV program for rheumatoid arthritis and diabetic nephropathy.
Risks
- Potential: Clinical trial failures for Remestemcel-L or other pipeline candidates.
- Potential: Regulatory setbacks or delays in obtaining marketing approvals.
- Ongoing: Competition from other regenerative medicine companies.
- Ongoing: High cash burn rate and need for additional financing.
- Potential: Intellectual property challenges or patent disputes.
Growth Opportunities
- Expansion of Remestemcel-L indications: Successful completion of Phase III clinical trials and subsequent regulatory approvals for Remestemcel-L in SR-aGVHD, chronic heart failure, and other indications could significantly expand the company's market reach. The market for SR-aGVHD treatment is estimated to reach hundreds of millions of dollars annually, while the market for chronic heart failure therapies is substantially larger. Timeline: 2026-2028.
- Strategic partnerships and licensing agreements: Mesoblast can leverage its proprietary technology platform to establish new partnerships and licensing agreements with pharmaceutical companies. These collaborations can provide upfront payments, milestone payments, and royalties on product sales, thereby diversifying revenue streams and reducing financial risk. Focus areas could include autoimmune diseases and musculoskeletal disorders. Timeline: Ongoing.
- Advancement of MPC-300-IV program: The development of MPC-300-IV for biologic-refractory rheumatoid arthritis and diabetic nephropathy represents a significant growth opportunity. If successful, this program could address large patient populations with unmet medical needs. The market for rheumatoid arthritis therapies is estimated to be billions of dollars annually. Timeline: 2027-2030.
- Geographic expansion: Mesoblast can expand its commercial operations into new geographic markets, such as Europe and Asia, to increase its global presence and access new patient populations. This expansion could be achieved through direct sales and marketing efforts or through partnerships with local distributors. Timeline: 2027 onwards.
- Development of next-generation cell therapies: Mesoblast can invest in the development of next-generation cell therapies with improved efficacy and safety profiles. This could involve modifying its existing mesenchymal lineage cell technology or exploring new cell types and delivery methods. Timeline: Ongoing research and development.
Opportunities
- Expansion of Remestemcel-L indications.
- Strategic partnerships and licensing agreements.
- Advancement of MPC-300-IV program.
- Geographic expansion into new markets.
Threats
- Clinical trial failures.
- Regulatory setbacks.
- Competition from other regenerative medicine companies.
- Intellectual property challenges.
Competitive Advantages
- Proprietary mesenchymal lineage cell technology platform.
- Extensive patent portfolio protecting its cell therapy products.
- Advanced clinical pipeline with Phase III assets.
- Strategic partnerships with established pharmaceutical companies.
About MEOBF
Mesoblast Limited, founded in 2004 and headquartered in Melbourne, Australia, is a global regenerative medicine company focused on developing innovative cellular medicines to address significant unmet medical needs. The company's proprietary technology platform is built upon mesenchymal lineage cells (MLCs), which are specialized cells with immunomodulatory and tissue repair properties. These cells are used to develop therapies for a range of inflammatory conditions and cardiovascular diseases. Mesoblast's lead product candidate is Remestemcel-L, an allogeneic (donor-derived) cell therapy currently in Phase III clinical trials. Remestemcel-L is being investigated for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), biologic-refractory inflammatory bowel disease (including ulcerative colitis and Crohn's disease), chronic heart failure, and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV for biologic-refractory rheumatoid arthritis and diabetic nephropathy. Mesoblast has established strategic partnerships with several pharmaceutical companies to expand the development and commercialization of its products. These partnerships include collaborations with Tasly Pharmaceutical Group for MPC-150-IM (chronic heart failure) and MPC-25-IC (acute myocardial infarction), JCR Pharmaceuticals Co. Ltd. for wound healing in epidermolysis bullosa and neonatal hypoxic ischemic encephalopathy, and Grünenthal for cell therapy for chronic low back pain. Mesoblast operates in Australia, the United States, Singapore, and Switzerland, reflecting its global approach to regenerative medicine development.
What They Do
- Develops regenerative medicine products based on mesenchymal lineage cells.
- Conducts Phase III clinical trials for Remestemcel-L to treat systemic inflammatory diseases.
- Targets steroid refractory acute graft versus host disease (SR-aGVHD) with Remestemcel-L.
- Aims to treat biologic refractory inflammatory bowel disease, ulcerative colitis, and Crohn's disease.
- Develops Remestemcel-L for chronic heart failure and chronic low back pain due to degenerative disc disease.
- Develops MPC-300-IV to treat biologic refractory rheumatoid arthritis and diabetic nephropathy.
- Forms strategic partnerships for product development and commercialization.
Business Model
- Develops and patents regenerative medicine technologies.
- Conducts clinical trials to demonstrate safety and efficacy of its products.
- Seeks regulatory approval from agencies like the FDA.
- Partners with pharmaceutical companies for commercialization and distribution.
Industry Context
Mesoblast operates within the rapidly evolving regenerative medicine industry, which is projected to experience substantial growth in the coming years. This growth is driven by increasing demand for novel therapies to treat chronic diseases and age-related conditions. The competitive landscape includes companies developing cell therapies, gene therapies, and tissue engineering products. Mesoblast's focus on mesenchymal lineage cells and its clinical-stage pipeline position it as a key player in this space. However, the industry is characterized by high regulatory hurdles and significant R&D costs.
Key Customers
- Patients with steroid refractory acute graft versus host disease (SR-aGVHD).
- Patients with biologic refractory inflammatory bowel disease, ulcerative colitis, and Crohn's disease.
- Patients with chronic heart failure.
- Patients with chronic low back pain due to degenerative disc disease.
- Patients with biologic refractory rheumatoid arthritis and diabetic nephropathy.
Financials
Chart & Info
Mesoblast Limited (MEOBF) stock price: Price data unavailable
Latest News
No recent news available for MEOBF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MEOBF.
Price Targets
Wall Street price target analysis for MEOBF.
MoonshotScore
What does this score mean?
The MoonshotScore rates MEOBF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
MEOBF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Mesoblast Limited may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure: The lack of comprehensive financial reporting increases the difficulty of assessing the company's financial health.
- Lower liquidity: Reduced trading volumes can lead to price volatility and difficulty in executing trades.
- Potential for fraud or manipulation: The OTC market is subject to less regulatory oversight, increasing the risk of fraudulent or manipulative activities.
- Delisting risk: Failure to meet minimum listing requirements could result in delisting from the OTC market.
- Verify the company's registration and regulatory filings.
- Review available financial statements and assess the company's financial condition.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the liquidity of the stock and the potential for price volatility.
- Consult with a financial advisor before investing.
- Check for any history of regulatory actions or legal disputes.
- Strategic partnerships with established pharmaceutical companies.
- Advanced clinical pipeline with Phase III assets.
- Experienced management team with expertise in regenerative medicine.
- Focus on addressing unmet medical needs in large patient populations.
Mesoblast Limited Stock: Key Questions Answered
What does Mesoblast Limited do?
Mesoblast Limited is a regenerative medicine company focused on developing and commercializing innovative cellular medicines to treat inflammatory diseases and cardiovascular conditions. The company's proprietary technology platform is based on mesenchymal lineage cells (MLCs), which are specialized cells with immunomodulatory and tissue repair properties. Mesoblast's lead product candidate, Remestemcel-L, is in Phase III clinical trials for several indications, including steroid-refractory acute graft versus host disease (SR-aGVHD) and chronic heart failure. The company also has strategic partnerships with pharmaceutical companies to develop and commercialize its products in various markets.
What do analysts say about MEOBF stock?
AI analysis is pending for MEOBF, so there is no analyst consensus available at this time. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions. Key valuation metrics to consider include the company's market capitalization, cash burn rate, and the potential market size for its pipeline products. Growth considerations include the successful completion of clinical trials, regulatory approvals, and the expansion of strategic partnerships.
What are the main risks for MEOBF?
The main risks for Mesoblast Limited include clinical trial failures, regulatory setbacks, competition from other regenerative medicine companies, a high cash burn rate, and the need for additional financing. Clinical trial failures could significantly impact the company's pipeline and future revenue potential. Regulatory setbacks or delays in obtaining marketing approvals could also negatively affect the company's prospects. Competition from other companies in the regenerative medicine space could limit Mesoblast's market share and pricing power. The company's high cash burn rate and need for additional financing could dilute existing shareholders or increase the company's debt burden.
What are the key factors to evaluate for MEOBF?
Mesoblast Limited (MEOBF) currently holds an AI score of 67/100, indicating moderate score. Key strength: Proprietary mesenchymal lineage cell technology platform.. Primary risk to monitor: Potential: Clinical trial failures for Remestemcel-L or other pipeline candidates.. This is not financial advice.
How frequently does MEOBF data refresh on this page?
MEOBF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven MEOBF's recent stock price performance?
Recent price movement in Mesoblast Limited (MEOBF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary mesenchymal lineage cell technology platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider MEOBF overvalued or undervalued right now?
Determining whether Mesoblast Limited (MEOBF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying MEOBF?
Before investing in Mesoblast Limited (MEOBF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for MEOBF, limiting the depth of financial analysis.
- OTC listing introduces higher risk factors.